Myriad Genetics Sees Unusually High Options Volume (MYGN)
Myriad Genetics, Inc. (NASDAQ:MYGN) saw some unusual options trading on Wednesday. Stock investors purchased 861 call options on the company. This is an increase of 806% compared to the typical volume of 95 call options.
Myriad Genetics stock opened at $44.86 on Thursday. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.19 and a quick ratio of 2.86. Myriad Genetics has a 12-month low of $27.23 and a 12-month high of $50.44. The stock has a market capitalization of $3.26 billion, a P/E ratio of 37.38, a price-to-earnings-growth ratio of 3.12 and a beta of 0.51.
Myriad Genetics (NASDAQ:MYGN) last released its quarterly earnings results on Tuesday, August 21st. The company reported $0.38 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.33 by $0.05. Myriad Genetics had a return on equity of 9.78% and a net margin of 17.69%. The business had revenue of $200.90 million during the quarter, compared to analysts’ expectations of $195.93 million. During the same period in the previous year, the business posted $0.30 earnings per share. The firm’s revenue for the quarter was up .7% compared to the same quarter last year. As a group, sell-side analysts predict that Myriad Genetics will post 1.44 EPS for the current fiscal year.
Several institutional investors have recently added to or reduced their stakes in the stock. CHICAGO TRUST Co NA bought a new position in shares of Myriad Genetics in the third quarter valued at about $230,000. United Services Automobile Association raised its holdings in shares of Myriad Genetics by 8.0% in the second quarter. United Services Automobile Association now owns 36,961 shares of the company’s stock valued at $1,381,000 after buying an additional 2,746 shares during the last quarter. Northern Trust Corp raised its holdings in shares of Myriad Genetics by 2.7% in the second quarter. Northern Trust Corp now owns 1,801,882 shares of the company’s stock valued at $67,337,000 after buying an additional 47,994 shares during the last quarter. Public Employees Retirement System of Ohio raised its holdings in shares of Myriad Genetics by 7.2% in the second quarter. Public Employees Retirement System of Ohio now owns 155,885 shares of the company’s stock valued at $5,825,000 after buying an additional 10,503 shares during the last quarter. Finally, GHP Investment Advisors Inc. raised its holdings in shares of Myriad Genetics by 4.5% in the second quarter. GHP Investment Advisors Inc. now owns 53,290 shares of the company’s stock valued at $1,991,000 after buying an additional 2,305 shares during the last quarter.
Myriad Genetics Company Profile
Myriad Genetics, Inc, a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; riskScore, a clinically validated personalized medicine tool; GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents.
Further Reading: How to Invest in Growth Stocks
Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.